Sanofi has 65 new compounds in development, says R&D President

Hannah Blake

pharmaphorum

Sanofi has begun 2013 on a positive note after announcing that it has 65 New Molecular Entity (NME) projects and vaccine candidates in clinical development. Of this 65, 17 are already in phase 3 clinical trials or have been submitted to the health authorities for approval.

“Sanofi has made significant progress in the transformation of its R&amp,D over the last couple of years, including advances in late stage projects and early stage pipeline as well as talent recruitment. We feel we have the ingredients to ensure R&amp,D contributes to Sanofi’s goal of sustainable growth in the coming years while rigorously managing R&amp,D costs.”

Dr. Elias Zerhouni, President, Global Research and Development, Sanofi.

In the next six months, Sanofi aims to reach the following key development milestones:

• In Q1, receive phase 3 results of the ENCORE study, which is evaluating the oral therapy eliglustat vs. cerezyme in patients with Gaucher disease.

• In Q2, receive phase 3 results of the TAO study evaluating otamixaban, the first intravenous direct and selective factor Xa inhibitor with quick onset / offset.

• In Q2, receive headline results from the phase 3 JAKARTA study evaluating SAR302503 as a treatment for myelofibrosis.

• In Q2, the first phase 3 headline results of the company’s new glargine formulation for diabetes is expected.

• In Q2, Sanofi expects to gain headline results from its phase 3 trials of Iniparib for first-line squamous non-small-cell lung cancer.

The global pharmaceutical company also expects to reach a number of regulatory milestones, including a European Commission decision on Zaltrap, its drug developed in collaboration with Regeneron for second-line metastatic colorectal cancer as well as European Commission and FDA approval of its type 2 diabetes drug Lyxumia, to name a few.

&nbsp,